Peiyuan Zhang

This paper designs an orally bioavailable small molecule that targets RNA to reduce 4R tau protein abundance and alleviate disease phenotypes in a mouse model.

This paper develops branched multimeric peptides that bind α-Klotho with high affinity and selectivity, enabling its detection and labeling in biological systems.

The paper designs a covalent peptide inhibitor, reactide, targeting the HPV16 E6-E6AP interaction to prevent p53 degradation.

The paper identifies structured regions in tau pre-mRNA that influence splicing and stability, potentially offering new therapeutic targets for tauopathies.